Tyra Biosciences, Inc. — Director's Dealing 2021

Sep 15, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-09-14

Reporting Person: MORE ROBERT J (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	112929	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$0.00		Common Stock (3148365)		Indirect
Series B Preferred Stock	$0.00		Common Stock (662752)		Indirect

Footnotes

F1: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.

F2: The shares of Series A Preferred Stock and Series B Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1-for-2.5974. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1-for-2.5974. The Series A Preferred Stock and Series B Preferred Stock has no expiration date.